GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination

Share this article
Share this article
NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of incorporation (the "Charter") to extend the date by which GX has to complete its initial business combination (the "Extension") from May 23, 2021 to July 31, 2021.
The Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an initial business combination, which is customary for a special purpose acquisition company like GX. As previously announced, in January 2021 GX entered into a definitive merger agreement with Celularity Inc. ("Celularity"), an allogeneic cellular therapy company, that would result in Celularity combining with GX and becoming a publicly listed company (the "Celularity Business Combination"). Since that time, GX and Celularity have been working together to address comments from the staff of the U.S. Securities and Exchange Commission ("SEC") on the proxy statement/prospectus filed in connection with the transaction and to satisfy the various closing conditions contained in the merger agreement. Additionally, in recent days the SEC made a public statement regarding accounting and reporting considerations for warrants issued by special purpose acquisition companies. GX has begun a complete review of its accounting treatment of its public and private warrants, and GX's board of directors currently believes that there may not be sufficient time before May 23, 2021 to complete the review and hold a special meeting to conduct a vote for the stockholder approvals required in connection with the Celularity Business Combination and consummate the closing of the Celularity Business Combination within the legally prescribed time constraints applicable to such actions. The GX board is seeking the Extension to complete the accounting review, to allow our stockholders to be able to evaluate the Celularity Business Combination and to allow additional time to consummate the Celularity Business Combination. The GX board continues to unanimously recommend that its stockholders vote "

Related Keywords

New York , United States , Delaware , Jason Braco , Carlos Ramirez , Alexandra Roy , Caroline Luz , Exchange Commission , Celularity Inc , Gx Acquisition Corp , Lifesci Communications , Lambert Co , Source Gx Acquisition Corp , Celularity Business Combination , Celularity Business , Extension Amendment , Amendment Special , Extension Amendment Special Meeting , Managing Partners , Trimaran Capital , Florham Park , Registration Statement , Proxy Statement , Securities Act , Private Securities Litigation Reform Act , Investor Contacts , Media Contact , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , டெலாவேர் , கார்லோஸ் ரெமிரெஸ் , அலெக்சாண்ட்ரா ராய் , கரோலின் லஸ் , பரிமாற்றம் தரகு , க்க்ஸ் கையகப்படுத்தல் கார்ப் , ல்யாம்‌பர்ட் இணை , நீட்டிப்பு திருத்தம் , நிர்வகித்தல் கூட்டாளர்கள் , புளோர்ஹாம் பூங்கா , பதிவு அறிக்கை , ப்ராக்ஸி அறிக்கை , பத்திரங்கள் நாடகம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , முதலீட்டாளர் தொடர்புகள் , மீடியா தொடர்பு ,